



ISSUE DATE April 6, 2012	EFFECTIVE DATE December 30, 2011	NUMBER 01-12-25, 08-12-26, 09-12-26, 31-12-26, 33-12-26
SUBJECT Updates to the Medical Assistance Program Fee Schedule for the Administration of Prevnar 13® Vaccine		BY  Vincent D. Gordon, Deputy Secretary Office of Medical Assistance Programs

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that effective for dates of service on and after December 30, 2011, the Department of Public Welfare (Department) is updating the MA Program Fee Schedule to allow payment for administration of the vaccine, Prevnar 13®, for MA recipients 50 years of age and older in accordance with the approved use of the vaccine by the U.S. Food and Drug Administration (FDA).

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospitals and independent medical surgical clinics enrolled in the MA Program who administer immunizations to MA recipients in the MA Fee-For-Service delivery system (including ACCESS Plus), and the MA Managed Care delivery system. Providers rendering services to MA recipients under the MA Managed Care delivery system should address any coding or rate-related questions to the appropriate managed care organization (MCO).

BACKGROUND/DISCUSSION:

On February 24, 2010, the FDA licensed Prevnar 13®, manufactured by Wyeth Pharmaceuticals, for prevention of invasive pneumococcal disease caused by the 13 pneumococcal serotypes covered by the vaccine and for prevention of otitis media caused by serotypes in the 7-valent pneumococcal conjugate vaccine formulation (PCV7). The 13-valent pneumococcal conjugate vaccine (PCV13), Prevnar 13®, is approved for use among children 6 weeks through 71 months of age and succeeds PCV7, Prevnar 7®, which was licensed by the FDA in 2000.

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
<http://www.dpw.state.pa.us/provider/healthcaremedicalassistance/index.htm>

The Department issued MA bulletin 01-10-27, et.al. titled "Updates to the Medical Assistance Program Fee Schedule for the Administration of the Vaccines Prevnar 13®, Cervarix®, Twinrix®, Recombivax HB®, and Menveo®" on August 30, 2010, to inform MA providers that on August 30, 2010, Prevnar 13® was added to the MA Program Fee Schedule for the administration of Prevnar 13® for MA recipients 6 weeks through 71 months of age.

On December 30, 2011, the FDA approved use of Prevnar 13® for individuals ages 50 years and older to prevent pneumonia and invasive disease caused by streptococcus pneumoniae bacterium. The FDA's Center for Biologics Evaluation and Research estimates that approximately 300,000 adults 50 years of age and older are hospitalized yearly in the United States because of pneumococcal pneumonia and that pneumococcal disease is a substantial cause of illness and death in this age group.

The Department is updating the MA Program Fee Schedule to allow payment for the administration of Prevnar 13® for MA recipients 50 years of age and older, effective for dates of service on and after December 30, 2011.

PROCEDURE:

Effective for dates of service on and after December 30, 2011, MA providers may bill the Department using CPT code 90670 (pneumococcal conjugate vaccine, 13 valent, for intramuscular use) for the administration of Prevnar 13® for MA recipients 50 years of age and older. The MA Program Fee Schedule has been updated to reflect this expanded age indication. The MA Program will continue to cover the administration of Prevnar 13® under CPT code 90670 for MA recipients 6 weeks through 71 months of age. Providers may access the on-line version of the fee schedule under the Department's website at:

http://www.dpw.state.pa.us/publications/forproviders/schedules/mafeeschedules/S_001967.

The MA fee for the administration of each vaccine is \$10.00 per administration. Providers participating in an MA MCO network must abide by payment arrangements as stated in their individual MCO contract.

MA providers may also bill the Department for the Prevnar 13® vaccine by indicating, on the claim submission, the appropriate National Drug Code for the vaccine dispensed. Providers may access the online version of the MA Drug Fee Schedule under the Department's website at:

<http://www.dpw.state.pa.us/publications/forproviders/schedules/drugfeeschedule/index.htm>.